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Abstract
Background: The optimal first-line chemotherapy for ovarian carcinosarcoma has not yet been determined. We
therefore sought to determine the progression-free survival (PFS) and overall survival (OS) for patients with ovarian
carcinosarcoma treated at our institution with different first-line chemotherapy regimens.
Methods: This single-institution, retrospective analysis included all patients with ovarian or primary peritoneal
carcinosarcoma diagnosed from September 1996 to July 2017. Kaplan Meier analysis with a log-rank Mantel-Cox
test was used to compare PFS and OS between treatment groups, and a p-value of < 0.05 was considered
statistically significant.
Results: Thirty-one patients met inclusion criteria: two patients were stage IC, 5 were stage II, 21 were stage III, and
3 were stage IV. The median PFS and OS for all stages was 9.3 and 19.7 months respectively. Fifteen patients (48%)
received carboplatin/paclitaxel as first therapy, 7 (23%) received ifosfamide/paclitaxel, 6 (19%) received a different
regimen, and 3 (10%) did not receive chemotherapy. Patients treated with carboplatin/paclitaxel had a statistically
significant longer PFS when compared to those receiving ifosfamide/paclitaxel (17.8 vs. 8.0 months, p = 0.025). OS
was similar between all comparisons.
Conclusions: In summary, in our cohort of ovarian carcinosarcoma patients, median PFS is longer in patients
treated with carboplatin/paclitaxel compared to ifosfamide/paclitaxel. Overall survival was similar for all treatment
groups, potentially due to subsequent treatment crossover. Given the rarity and aggressive nature of this tumor,
further study into optimal first-line chemotherapy is warranted.
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Background
Ovarian carcinosarcomas, also known as malignant
mixed Mullerian tumors (MMMT), represent 1% of all
histologic subtypes of ovarian cancers and remain poorly
understood [1]. While ovarian carcinosarcomas were
once thought to be “collision tumors” with the presence
of synchronous epithelial carcinoma and stromal sar-
coma components, current data suggest they are de-
differentiated carcinomas with cells that have a sarcoma-
tous appearance and also cells with a carcinomatous
histology [2]. Importantly, carcinosarcomas have been
shown in multiple studies to be aggressive tumors, with
one-third of patients having advanced disease at the time
of diagnosis and a 60% overall recurrence rate [1, 3]. A
review of the Surveillance, Epidemiology, and End Re-
sults (SEER) Program data from 1998 to 2009 demon-
strated that patients with ovarian carcinosarcoma have
consistently poorer prognosis than those with high-
grade papillary serous carcinoma of the ovary. This study
consisted of more than 14,000 ovarian cancer patients,
approximately 9% of whom had ovarian carcinosarcoma,
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and the five-year disease specific survival rate was 28.2%
for carcinosarcoma patients compared to 38.4% for
high-grade papillary serous carcinoma patients (p <
0.001) [4]. Several additional single institution studies
have also demonstrated that ovarian carcinosarcoma pa-
tients have lower response rates to chemotherapy and
worse overall and disease-specific survival [4–7]. Given
the low incidence of these tumors, prospective trials of
chemotherapeutic approaches have been difficult to per-
form [8]. Thus, the preferred first-line chemotherapy for
ovarian carcinosarcoma patients remains unknown.
Data guiding chemotherapy for the treatment of ovar-
ian carcinosarcoma is largely extrapolated from studies
on the treatment of uterine carcinosarcoma. Historically,
ovarian carcinosarcomas were often treated with the
same first-line chemotherapy as uterine carcinosar-
comas, ifosfamide/paclitaxel [9, 10]. Additionally, mul-
tiple phase II studies investigating the use of
carboplatin/paclitaxel in uterine carcinosarcoma demon-
strated efficacy with this regimen [11, 12]. These studies
have formed the basis of the Gynecologic Oncology
Group (GOG) study 261, a phase III randomized, con-
trolled trial comparing ifosfamide/paclitaxel to carbopla-
tin/paclitaxel in the treatment of gynecologic
carcinosarcomas, which allowed enrollment of patients
with uterine or ovarian primary tumor sites.
Despite the above studies investigating chemotherapy
treatment options for uterine carcinosarcoma, there are
no published prospective studies looking at treatment
options for ovarian carcinosarcoma. Small case
series have reported on the efficacy of these and
other regimens in the treatment of ovarian carcino-
sarcoma [5, 13–17]. We sought to determine the
progression-free survival (PFS) and overall survival (OS)
for patients with ovarian and primary peritoneal carcino-
sarcoma treated at our institution comparing different
first-line chemotherapy regimens. Given the historical use
of ifosfamide/paclitaxel and carboplatin/paclitaxel, we
sought to compare these two regimens specifically as well
as to compare platinum-containing regimens to non-
platinum-containing regimens.
Methods
This single-institution, retrospective study investigated
patients with a pathologic diagnosis of ovarian, tubal, or
primary peritoneal carcinosarcoma from September
1996 to July 2017. This study was approved by the
University of Michigan Institutional Review Board (IRB
# HUM00099459). Thirty-one patients with a histologic
diagnosis of ovarian or primary peritoneal carcinosar-
coma were identified (all cases were reviewed by a gyne-
cologic pathologist). Baseline demographic information
including age at diagnosis, stage, extent of cytoreduction
(with optimal debulking defined as less than two
centimeters of residual disease), and race were ab-
stracted from each patient’s medical chart. First-line
chemotherapy regimen was determined. Date of diagno-
sis was defined as date of primary debulking surgery or
the date of diagnostic biopsy in the case of patients for
whom debulking surgery was not undertaken.
Progression-free survival (PFS) was defined as time from
diagnosis to first evidence any of the following: appear-
ance of new disease via radiographic imaging or clinical
exam, elevation in CA125 above the normal range, or
patient death from any cause. Overall survival (OS) was
defined as months from diagnosis to patient death or
last contact.
For statistical analysis, results were analyzed with
standard descriptive and inferential statistical methods
using SPSS Statistics 22. Mean age at diagnosis was
compared using a one-way ANOVA. For categorical
demographic variables, a chi-squared test was per-
formed. Grubbs’ test for outliers was applied. Kaplan
Meier curves were plotted for PFS and OS by initial
chemotherapy regimen, and a log-rank Mantel-Cox test
was used to compare PFS and OS between groups. Re-
gression modeling was not performed due to small sam-
ple size. A p-value of < 0.05 was deemed statistically
significant for all comparisons.
Results
Thirty-one patients met inclusion criteria (Table 1). All
patients were Caucasian race, and the mean age at diag-
nosis was 65.3 years (range 36–89 years). Twenty-nine
patients had primary surgical debulking attempted, with
optimal debulking achieved in 19 cases, suboptimal
debulking in 9 cases and one case for which residual dis-
ease could not be determined from the medical record.
Two patients did not undergo primary surgical debulk-
ing owing to their advanced stage and poor functional
status at the time of diagnosis. With regard to stage at
diagnosis, 7 patients were stage IC or II at diagnosis
(22%), 21 patients were stage III (68%), and 3 patients
were stage IV (10%). In our cohort, twenty-eight patients
(90%) received chemotherapy. Fifteen patients (48%) re-
ceived carboplatin/paclitaxel as their first chemotherapy,
7 patients (23%) received ifosfamide/paclitaxel, 6 pa-
tients (19%) received a different regimen and 3 patients
(10%) did not receive chemotherapy. Only one patient
(3%) received post-operative radiation.
Table 1 legend: Categorical variables are presented as
“n” (%). Continuous variables are presented as mean ±
standard deviation. Patients in the “Other Platinum” cat-
egory include those receiving Ifosfamide/Cisplatin, Car-
boplatin/Cytoxan, and Adriamycin/Cisplatin. P-values
represent the following comparisons between the five
chemotherapy groups: one-way ANOVA for mean age at
diagnosis and chi-squared for stage, debulking status,
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and radiation. There were no significant differences be-
tween the chemotherapy groups for these variables.
Seventeen patients (55%) achieved a complete re-
sponse, defined as no measurable evidence of disease
on imaging and clinical exam following completion of
primary chemotherapy. Eighteen patients (58%) were
alive one year after diagnosis, 6 patients (19%) two
years after diagnosis and 3 patients (10%) five years
after diagnosis. The median PFS and OS by first-line
chemotherapy regimen are presented in Table 2. For
the entire cohort, the median progression-free sur-
vival was 9.3 months (95% CI: 3.7–14.9 months), and
the median overall survival was 19.7 months (95% CI:
15.7–23.6 months). The one patient treated with cis-
platin/Adriamycin (stage IIIC at diagnosis) had a PFS
and OS of 213.2 months, and was excluded from fur-
ther analysis after the application of Grubbs’ test for
outliers (p < 0.05).
Table 2 legend: PFS and OS are reported for each
chemotherapy regimen as “Median (95% confidence
interval).”
Next PFS and OS were directly compared by first-line
chemotherapy regimen. Median progression-free sur-
vival for patients receiving no chemotherapy was
1.3 months (95% CI: 0.5–2.1 months). The three patients
who did not receive chemotherapy (all stage IIIC at diag-
nosis) were all determined to have too poor of a per-
formance status to receive chemotherapy. Given the
common clinical use of chemotherapy doublets ifosfa-
mide/paclitaxel and carboplatin/paclitaxel based on uter-
ine carcinosarcoma literature, we sought to compare
these two specific regimens in our ovarian carcinosar-
coma cohort. Kaplan-Meier curves were plotted for PFS
and OS for the two treatment groups and comparison car-
ried out with a log-rank Mantel-Cox test (Fig. 1a and b).
In comparing the outcomes for carboplatin/paclitaxel as a
first-line regimen versus to ifosfamide/paclitaxel, those re-
ceiving carboplatin/paclitaxel had a median PFS of
17.8 months (95% CI: 4.0–31.6 months) compared to a
median PFS of 8.0 months (95% CI: 2.4–13.7 months) for
ifosfamide/paclitaxel (p = 0.025), representing a statisti-
cally significant improvement in PFS with carboplatin/
paclitaxel as first-line chemotherapy (Fig. 1a). OS was
similar between groups in this comparison with a me-
dian OS of 23.2 months (95% CI: 22.0–24.4 months)
for carboplatin/paclitaxel and 19.0 months (95% CI:
16.4–21.6 months) for ifosfamide/paclitaxel (p = 0.350)
(Fig. 1b).
Kaplan-Meier curves were similarly plotted for PFS
and OS for both platinum and non-platinum containing
regimens (Fig. 2a and b), and they were compared with a
log-rank Mantel-Cox test. In comparing platinum to
non-platinum containing regimens, the median PFS for
platinum-containing regimens was longer at 13.4 months
compared to 8.0 months for non-platinum regimens
Table 1 Demographic information by initial chemotherapy regimen with regard to age, stage, debulking surgery, and radiation







Total N 31 3 (10%) 15 (48%) 7 (23%) 6 (19%)
Mean age at diagnosis
(yrs ± St dev.)
65.39 ± 11.3 70.67 ± 7.6 68.33 ± 11.3 59.29 ± 4.4 62.50 ± 16.1 0.257
STAGE
Stage IC-II 7 (22.6%) 0 (0%) 4 (26.7%) 2 (28.6%) 1 (16.7%) 0.736
Stage III 21 (67.7%) 3 (100%) 9 (60%) 4 (57.1%) 5 (83.3%)
Stage IV 3 (9.7%) 0 (0%) 2 (13.3%) 1 (12.3%) 0 (0%)
DEBULKING STATUS
Debulking Surgery 29 (93.5%) 3 (100%) 14 (93.3%) 6 (85.7%) 6 (100%) 0.562
Optimal debulking 19 (61.3%) 1 (33.3%) 10 66.7%) 4 (57.1%) 4 (66.6%)
Suboptimal debulking 9 (29.0%) 2 (66.7%) 4 (26.6%) 2 (28.6%) 1 (16.7%)
Unknown Status 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 1 (16.7%)
No Surgery Attempted 2 (6.5%) 0 (0%) 1 (6.7%) 1 (14.3%) 0 (0%)
Radiation 1 0 0 0 1 NA
Table 2 Median progression-free survival and overall survival by
initial chemotherapy regimen
First line chemotherapy N Median PFS (95% CI) Median OS (95% CI)
No chemotherapy 3 1.3 (0.5–2.1) 1.3 (0.5–2.1)
Ifosfamide/Paclitaxel 7 8.0 (2.4–13.7) 19.0 (16.4–21.6)
Carboplatin/Paclitaxel 15 17.8 (4.0–31.6) 23.2 (22.0–24.4)
Ifosfamide/Cisplatin 4 13.0 (0.0–28.3) 20.6 (0.0–65.2)
Carboplatin/Cytoxan 1 13.4 (NA) 13.4 (NA)
Adriamycin/Cisplatin 1 213.2 (NA) 213.2 (NA)
Total 31 9.3 (3.7–14.9) 19.7 (15.7–23.6)
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(p = 0.008). Overall survival was similar between the two
groups at a median of 22.7 months for platinum-
containing regimens and 19.0 months for non-platinum-
containing regimens (p = 0.323). Given the potential that
the platinum component of the chemotherapy doublet is
critical to the effectiveness of the regimen, we made one
additional comparison: ifosfamide/cisplatin (n = 4) com-
pared to carboplatin/paclitaxel (n = 15). There was no
difference in median PFS (13.0 vs 17.8 months, p =
0.750) or OS (20.6 vs 23.2 months, p = 0.657) between
these platinum-containing groups.
Discussion
This retrospective study suggests that utilizing carbopla-
tin/paclitaxel as first-line chemotherapy improves
progression-free survival in patients with ovarian carci-
nosarcoma when compared to ifosfamide/paclitaxel.
Interestingly, comparison of the patient population in
our cohort treated with carboplatin/paclitaxel compared
to ifosfamide/paclitaxel revealed that the carboplatin/
paclitaxel patients were older (mean age of 68.3 years
versus 59.3 years, p = 0.014) yet still had a longer PFS.
Otherwise, there was no statistically significant
Fig. 1 Progression-Free Survival and Overall Survival for Ifosfamide/Paclitaxel vs Carboplatin/Paclitaxel. a Kaplan Meier curve comparing PFS by
initial chemotherapy: Ifosfamide/Paclitaxel compared to Carboplatin/Paclitaxel. Analyzed by log-rank Mantel-Cox test. p = 0.025. b Kaplan Meier
curve comparing OS by initial chemotherapy: Ifosfamide/Paclitaxel compared to Carboplatin/Paclitaxel. Analyzed by log-rank Mantel-Cox
test. p = 0.350
Fig. 2 Progression-Free Survival and Overall Survival for Platinum-Containing vs Non-Platinum-Containing Regimens. a Kaplan Meier curve comparing
PFS by initial chemotherapy: platinum-containing compared to non-platinum-containing. Analyzed by log-rank Mantel-Cox test. p = 0.008. b Kaplan
Meier curve comparing OS by initial chemotherapy: platinum-containing compared to non-platinum-containing. Analyzed by log-rank Mantel-Cox
test. p = 0.323
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difference between these two groups with regard to mul-
tiple variables: the percentage of patients that underwent
debulking surgery (carboplatin/paclitaxel 93% versus
ifosfamide/paclitaxel 86%, p = 0.34), the percentage in
whom optimal debulking was achieved (71% versus 65%,
p = 0.83), distribution of stage (60% stage III vs 57%, p =
0.736), or the percentage in whom complete response
was achieved following initial therapy (80% vs 57%, p =
0.26) (Table 1).
No treatment approach queried demonstrated a super-
ior overall survival as compared to other treatment op-
tions. We hypothesize that this is due to subsequent
treatment cross-over following progression or recur-
rence, such that many patients receive all of the poten-
tially active chemotherapy agents at some time during
their treatment. Due to post-progression therapy impact-
ing OS in the treatment of ovarian cancer, it has been
proposed that PFS be used as a valid endpoint for the as-
sessment of treatment efficacy [18].
The relative rarity of ovarian carcinosarcoma has lim-
ited the ability to perform prospective trials assessing
chemotherapy options. A Cochrane review of chemo-
therapy and/or radiotherapy in combination with surgery
for ovarian carcinosarcoma found no evidence to inform
decisions about neoadjuvant or post-operative chemo-
therapy for women with ovarian carcinosarcoma [19].
Additionally, data from GOG-261, which allowed for en-
rollment of patients with ovarian carcinosarcoma in
addition to uterine carcinosarcoma, is not yet available,
and we do not know yet how many ovarian carcinosar-
coma patients were enrolled in the study. Thus, we are
currently limited to retrospective studies to guide treat-
ment approaches. Multiple small studies have investi-
gated prognosis and treatment options for ovarian
carcinosarcoma (Table 3).
Table 3 legend: Studies are listed in the order they ap-
pear in the text. For each study, the number of partici-
pants, median PFS and OS, as well as key findings are
listed. If the study compared different chemotherapy
regimens directly, it is listed. “ND” = not determined.
Although several of these studies attempted to com-
pare different potential chemotherapy regimens, no de-
finitive preferred first-line treatment has emerged. In the
few studies where direct comparisons between regimens
were made, results were mixed. In one study, PFS was
longer in patients treated with ifosfamide/cisplatin com-
pared to carboplatin/paclitaxel [14]. However, in another,
PFS was the same when comparing ifosfamide/cisplatin
to carboplatin/paclitaxel [15]. Additionally, no study
prior to our work directly compares ifosfamide/pacli-
taxel to carboplatin/paclitaxel, an especially relevant
comparison given the frequent extrapolation of uterine
carcinosarcoma treatment regimens to the care of
women with ovarian carcinosarcoma [9, 10]. Our study
adds to the published literature by addressing this com-
parison. Moreover, our data further lend support to the
first-line use of platinum-based regimens in ovarian car-
cinosarcoma, consistent with our evolving understanding
Table 3 Key retrospective studies of chemotherapy regimens in patients with ovarian carcinosarcomas
Study Citation N Median PFS (mo) Median OS (mo) Findings Regimens
Compared
Brown, E. et al. [6] 65 6.4 8.2 Ovarian carcinosarcomas are associated with poorer response
to chemotherapy, PFS and disease specific survival compared
to high grade papillary serous carcinoma of the ovary.
Debulking status significantly impacts outcomes.
No
Kanis, M.J. et al. [13] 28 10 21 No difference in PFS and OS between patients treated with
carboplatin/paclitaxel and those treated with other first-line
chemotherapy regimens. Optimal debulking improves PFS.
Yes
Rutledge, T.L. et al. [14] 31 ND 21 Advanced stage disease worsens PFS. PFS is better in
ifosfamide/cisplatin compared to carboplatin/paclitaxel. OS
similar between the two chemotherapy regimens.
Yes
Silasi, D.A. et al. [15] 22 6–13 38 PFS is the same for ifosfamide/cisplatin compared to
carboplatin/paclitaxel.
Yes
Rauh-Hain, J.A. et al. [17] 50 11 24 Ovarian carcinosarcomas are associated with poorer response
to platinum-based chemotherapy, PFS and disease specific
survival compared to high grade papillary serous carcinoma
of the ovary.
No
Cicin, I. et al. [19] 26 ND 26 Median survival is longer with early versus late stage disease.
Adjuvant platinum-based chemotherapy is predictive of better
outcome.
Yes
Leiser, A.L. et al. [20] 30 12 43 Median PFS is 12 months when treated with combination of
a platinum and taxane.
No
Brackmann, M. et al. – 31 9.3 19.7 Longer PFS with carboplatin/paclitaxel compared to
ifosfamide/paclitaxel. OS similar between comparison groups.
Yes
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of carcinosarcomas as epithelial malignancies and previ-
ous reports supporting this approach [16, 20–25]. Given
the lower morbidity of carboplatin/paclitaxel in compari-
son to regimens containing ifosfamide, cisplatin, or both,
our comparison is of particular interest. Our work is
similar in sample size to previously reported studies and
PFS and OS are in line with published data.
Our study has similar limitations to previously pub-
lished work, including overall low patient numbers, the
retrospective nature of the work, the non-randomized
treatment groups (including some shift in chemotherapy
preference over time) and the high crossover rate with
subsequent therapies that confounds interpretation of
overall survival. Additionally, several patients in the co-
hort represent recent diagnoses and their survival data is
not yet mature. We plan an additional analysis of these
patients in the future.
As our understanding of tumor biology expands, con-
tinued molecular characterization of ovarian carcinosar-
coma is warranted to define both targetable alterations
and predictive biomarkers of response. Significant pro-
gress was made in this regard with the finding that ovar-
ian and uterine carcinosarcomas represent metaplastic
carcinomas, therefore suggesting traditional regimens
for carcinomas would be favored over sarcoma regimens
[2]. These data support the biologic rationale for treating
ovarian carcinosarcoma patients with carboplatin/pacli-
taxel, consistent with preferred treatment for ovarian
carcinomas. Detailed molecular analysis of ovarian carci-
nosarcomas remains lacking at this time. Studies are
generally still performed with both ovarian and uterine
carcinosarcomas to increase sample size, although it is
unclear whether there is a molecular rationale for this
approach. It is known, however, that altered expression
of p53 is frequent in gynecologic carcinosarcomas [26].
A recent molecular characterization of an ovarian carci-
nosarcoma patient-derived xenograft revealed p53 and
phosphoinositide-3-kinase, catalytic, alpha polypeptide
(PIK3CA) mutations, as well as epidermal growth factor
receptor overexpression, vascular endothelial growth fac-
tor receptor C overexpression and activation of the
insulin-like growth factor pathway [27]. Further studies
are warranted to determine the frequency of both germ-
line and somatic genetic alterations in ovarian carcino-
sarcoma patients and the potential for such mutations to
inform clinical treatment decisions.
Conclusions
In conclusion, ovarian carcinosarcomas are rare, aggres-
sive tumors with poor prognosis. The optimal first-line
chemotherapy for these patients remains unknown. In
our study, patients treated with carboplatin/paclitaxel
have a longer PFS than patients treated with ifosfamide/
paclitaxel. Moreover, platinum-containing regimens
appear to prolong PFS when compared to non-platinum
containing regimens. Overall survival was similar for all
treatment groups, likely due to subsequent treatment
crossover at the time of recurrence. Given lower mor-
bidity, lower cost and fewer hospital days associated with
carboplatin/paclitaxel regimens as well as longer PFS, we
favor this first-line chemotherapy for ovarian carcinosar-
comas after primary surgical debulking. Further study
into optimal chemotherapy remains warranted, including
cooperative clinical trials and continued molecular
characterization of ovarian carcinosarcomas.
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